Ana de Vera
Overview
Explore the profile of Ana de Vera including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
1123
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Capkun G, Schmidt J, Ghosh S, Sharma H, Obadia T, de Vera A, et al.
Theor Biol Med Model
. 2019 Nov;
16(1):17.
PMID: 31694651
Background: Associations between disease characteristics and payer-relevant outcomes can be difficult to establish for rare and progressive chronic diseases with sparse available data. We developed an exploratory bridging model to...
2.
Hanna M, Badrising U, Benveniste O, Lloyd T, Needham M, Chinoy H, et al.
Lancet Neurol
. 2019 Aug;
18(9):834-844.
PMID: 31397289
Background: Inclusion body myositis is an idiopathic inflammatory myopathy and the most common myopathy affecting people older than 50 years. To date, there are no effective drug treatments. We aimed...
3.
Bagel J, Nia J, Hashim P, Patekar M, de Vera A, Hugot S, et al.
Dermatol Ther (Heidelb)
. 2018 Oct;
8(4):571-579.
PMID: 30334147
Introduction: Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, has demonstrated superior efficacy to ustekinumab in the phase 3b CLEAR study of moderate to severe plaque psoriasis. Here, we report 16-week...
4.
Montalban X, Comi G, Antel J, OConnor P, de Vera A, Cremer M, et al.
J Neurol
. 2015 Sep;
262(12):2627-34.
PMID: 26338810
Fingolimod safety and efficacy data in relapsing-remitting multiple sclerosis (RRMS) are available up to 5 years, from an extension of a randomized, placebo-controlled, double-blind, phase 2 study, at a dose...
5.
Kappos L, Cohen J, Collins W, de Vera A, Zhang-Auberson L, Ritter S, et al.
Mult Scler Relat Disord
. 2015 Apr;
3(4):494-504.
PMID: 25877062
Background: Fingolimod 0.5mg once daily is the first approved oral therapy for relapsing multiple sclerosis (MS). Objective: To report integrated long-term safety data from phase 2/3 fingolimod studies. Methods: Descriptive...
6.
Radue E, Barkhof F, Kappos L, Sprenger T, Haring D, de Vera A, et al.
Neurology
. 2015 Jan;
84(8):784-93.
PMID: 25632085
Objective: We investigated the determinants and clinical correlations of MRI-detected brain volume loss (BVL) among patients with relapsing-remitting multiple sclerosis from the phase 3 trials of fingolimod: FREEDOMS, FREEDOMS II,...
7.
Barkhof F, Jong R, Sfikas N, de Vera A, Francis G, Cohen J
Mult Scler
. 2014 May;
20(13):1704-13.
PMID: 24812043
Background: Patients with multiple sclerosis (MS) lose brain volume (BV) faster than healthy individuals. Objective: Our purpose, within the 12-month phase 3 TRANSFORMS study, was to examine the effect of...
8.
Radue E, OConnor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, et al.
Arch Neurol
. 2012 Jul;
69(10):1259-69.
PMID: 22751847
Objective: To assess the impact of fingolimod (FTY720) therapy on magnetic resonance imaging measures of inflammatory activity and tissue damage in patients participating in a 2-year, placebo-controlled, phase 3 study....
9.
Cohen J, Barkhof F, Comi G, Hartung H, Khatri B, Montalban X, et al.
N Engl J Med
. 2010 Jan;
362(5):402-15.
PMID: 20089954
Background: Fingolimod (FTY720), a sphingosine-1-phosphate-receptor modulator that prevents lymphocyte egress from lymph nodes, showed clinical efficacy and improvement on imaging in a phase 2 study involving patients with multiple sclerosis....